Extended ECG Monitoring Boosts Arrhythmia
The ASPIRED trial found that immediate 14-day cardiac monitoring for emergency department patients with unexplained fainting doubled arrhythmia diagnosis
Immediate 14-day cardiac monitoring for emergency department patients with unexplained fainting more than doubled the diagnosis of clinically significant arrhythmias. The strategy also halved all-cause mortality at one year, according to results from the ASPIRED trial presented at the European Society of Cardiology Congress and published in the New England Journal of Medicine.
Researchers led by Dr. Matthew James Reed of the Usher Institute at Edinburgh University randomized 2,234 patients across 45 U.K. hospitals. Participants were 16 years or older and had syncope that remained unexplained after an initial ED evaluation. They were assigned to either immediate monitoring with a BodyGuardian Mini adhesive heart patch or to standard care.
Trial Design and Primary Outcome
The study was open-label. The intervention group was fitted with the waterproof monitor as soon as possible after their index ED visit and wore it for 14 days. All participants recorded fainting episodes in a paper diary. The primary analysis included 1,970 patients after accounting for loss to follow-up.
The main finding was that the mean number of patient-reported fainting episodes at one year was similar between the two groups.
| Measure | Extended Monitoring Group | Standard Care Group |
|---|---|---|
| Mean Syncope Episodes (1 year) | 1.37 | 1.58 |
| Incidence Rate Ratio | 0.89 (95% CI 0.68-1.18) | - |
Dr. Reed reported the intervention did not reduce patient-reported syncope episodes. Technically, this makes ASPIRED a negative trial for its primary endpoint.
Key Secondary Benefits Emerge
Despite no change in fainting frequency, the extended monitoring protocol yielded significant clinical benefits. It dramatically improved the detection of serious heart rhythm problems and was linked to a substantial survival advantage.
| Outcome | Extended Monitoring Group | Standard Care Group | Ratio (95% CI) |
|---|---|---|---|
| Clinically Significant Arrhythmia Diagnosis | 22.0% | III | 2.95 (2.28-3.81) |
| All-Cause Mortality at 1 Year | 1.5% | 2.9% | 0.50 (0.27-0.93) |
Early monitoring also reduced the median time to arrhythmia detection from approximately 55 days to 22 days. More patients subsequently received prompt, targeted treatment like permanent pacemakers or antiarrhythmic drugs. We believe this provides a biologically plausible mechanism for our 1-year survival benefit, Reed told the ESC audience.
Expert Interpretation and Mechanisms
Session discussant Dr. Michele Brignole of IRCCS Istituto Auxologico in Milan called the mortality reduction very important but questioned a direct cause-effect link. The direct cause-effect relationship between arrhythmias and all-cause mortality remains uncertain, probably unlikely, Brignole argued. He suggested an alternative mechanism where the mortality benefit reflects more thorough investigation following an arrhythmia diagnosis, rather than the arrhythmia itself.
The trial protocol allowed all participants to be referred to a syncope specialist, ideally within six weeks. When the monitor detected a serious arrhythmia, the patient's local clinical team was notified within 24 working hours. Treatment decisions were left to the treating clinician.
Safety and Trial Limitations
Adverse events were mostly minor. The investigators logged 49 events in the intervention group versus eight in the control group. Most in the monitoring group were due to minor skin irritation from the adhesive patch.
There was one serious adverse event in each group. One involved an infection of an implantable loop recorder in the monitoring group, requiring device removal. The other was a hematoma at a pacemaker site in the standard care group, treated with outpatient antibiotics. The trial authors judged both events unrelated to the study intervention.
Reed and colleagues acknowledged limitations, including the open-label design and a lower-than-anticipated rate of recurrent fainting. They noted that the ongoing REMOSYNCED study may provide external validation in a different care setting. The ASPIRED trial builds on prior evidence that initiating cardiac monitoring early, ideally at the first ED visit, offers the best chance of diagnosing the cause of unexplained fainting.
